Ohr Pharmaceuticals (OHRP) Stock Rating Lowered by ValuEngine

Ohr Pharmaceuticals (NASDAQ:OHRP) was downgraded by research analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research report issued on Friday.

Several other research firms have also recently commented on OHRP. Zacks Investment Research upgraded shares of Ohr Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 price target for the company in a report on Wednesday, October 18th. Roth Capital cut shares of Ohr Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $7.00 price target for the company. in a report on Friday.

Ohr Pharmaceuticals (NASDAQ:OHRP) traded down $1.64 during mid-day trading on Friday, hitting $0.38. 34,330,000 shares of the company traded hands, compared to its average volume of 2,340,000. The firm has a market capitalization of $21.19, a PE ratio of -0.64 and a beta of 0.48. Ohr Pharmaceuticals has a twelve month low of $0.35 and a twelve month high of $2.18.

A number of hedge funds and other institutional investors have recently bought and sold shares of OHRP. Wedbush Securities Inc. acquired a new stake in Ohr Pharmaceuticals in the third quarter valued at approximately $311,000. Garrison Bradford & Associates Inc. lifted its stake in Ohr Pharmaceuticals by 482.4% in the third quarter. Garrison Bradford & Associates Inc. now owns 497,415 shares of the biotechnology company’s stock valued at $358,000 after acquiring an additional 412,000 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in Ohr Pharmaceuticals by 0.7% in the second quarter. Vanguard Group Inc. now owns 812,418 shares of the biotechnology company’s stock valued at $520,000 after acquiring an additional 5,481 shares during the last quarter. Hedge funds and other institutional investors own 8.25% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/05/ohr-pharmaceuticals-ohrp-stock-rating-lowered-by-valuengine.html.

About Ohr Pharmaceuticals

OHR Pharmaceutical, Inc, a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Ohr Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ohr Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply